FDA Draft Guidance on AI-Enabled Device Software: Key Takeaways for Industry

On January 6, 2025, the U.S. Food and Drug Administration (FDA) released draft guidance on the development, lifecycle management, and marketing submissions for AI-enabled device software. The guidance builds on prior FDA and IMDRF work and reflects the agency’s evolving expectations for adaptive and data-driven technologies.

Key Lifecycle and Submission Considerations

The FDA emphasizes a total product lifecycle (TPLC) approach for AI-enabled devices. Manufacturers are expected to integrate AI-specific design controls, robust risk management, data governance, and post-market monitoring throughout development and commercialization. For marketing submissions (e.g., 510(k), De Novo, PMA), the guidance highlights the importance of clearly describing the AI model, training and validation datasets, performance limits, human oversight, and plans for managing future model changes, including Predetermined Change Control Plans (PCCPs).

Implications for Manufacturers

Manufacturers will need stronger cross-functional alignment between R&D, quality, regulatory, and clinical teams. Documentation expectations increase, particularly around algorithm transparency, bias mitigation, real-world performance monitoring, and change management. Companies that lack a mature software life cycle and data management processes may face longer review timelines or additional FDA questions.

Challenges and Regulatory Pitfalls

Key challenges for manufacturers include managing continuously learning models, ensuring representative data, and maintaining regulatory compliance as algorithms evolve. Regulators, in turn, face difficulties assessing model explainability, validating real-world performance at scale, and balancing innovation with patient safety in a rapidly changing AI landscape.

For more information, visit https://eemedicals.com/